Even without formal trial data on sequencing, clinicians are beginning to prescribe one oral SERD after progression on another (e.g., vepdegestrant after imlunestrant). This practice is driven by a belief in targeting the driving ESR1 mutation and by patient-specific factors like toxicity aversion, highlighting a real-world clinical need.

The Lidara study showed SERD benefit in patients without pre-existing ESR1 mutations. Success is likely multifactorial: SERDs are more effective and better tolerated than AIs. Critically, they also prevent the most common resistance mechanism—the acquisition of ESR1 mutations—from developing in the first place, altering the disease's future trajectory.

A subtle but significant quality-of-life benefit of oral SERDs over AIs is their mechanism allows for the safe use of topical vaginal estrogens. This is a major advantage for younger patients who struggle with genitourinary symptoms but cannot use estrogens with AIs due to the risk of systemic absorption and spillover effects.

Selective Estrogen Receptor Degraders (SERDs) are a mechanistic advance over older therapies. While drugs like tamoxifen merely block estrogen receptors and AIs reduce estrogen, SERDs both block the receptor and trigger its complete degradation, removing the target altogether.

The failure of Roche's gerodestrant when combined with a CDK4/6 inhibitor suggests these oral SERDs may not add benefit to that backbone. This contrasts with its success alone in an adjuvant setting, reframing the drugs as an "either-or" choice rather than a combination therapy in the first-line setting.

Uniquely, the EMPRIS window study in premenopausal patients showed geridestran monotherapy was more effective at suppressing proliferation than tamoxifen without adding an LHRH agonist. This challenges the standard practice of mandatory ovarian function suppression and could simplify treatment for younger women.

An ESR1 mutation locks the estrogen receptor in a permanently "on" state, independent of estrogen. This renders aromatase inhibitors (AIs) ineffective but means therapies that degrade the receptor itself, like SERDs, can still be effective treatment options.

The Phase 3 Ladera study found gerodestrin not only reduced the risk of recurrence by 30% over standard endocrine therapy but also caused fewer treatment discontinuations due to side effects. This dual benefit of superior efficacy and improved tolerability represents a significant potential advancement for patients with ER-positive early breast cancer.

The LADERA trial found that while dose interruptions were slightly higher with the oral SERD gerodestrant, treatment discontinuations were lower compared to standard of care. Specifically, fewer patients stopped treatment due to musculoskeletal symptoms, suggesting a clinically meaningful advantage in patient adherence.